Background: Patients with previously treated non-small-cell lung cancer (NSCLC) have
limited treatment options. A novel treatment based on programmed death 1 (PD-1)/programed death
ligand 1 (PD-L1) inhibitors has emerged as promising therapeutic options for advanced NSCLC. We
assessed oncological outcomes of PD-L1 antibody versus docetaxel in previously treated NSCLC.
Objectives: The purpose of this meta-analysis was to analyse the oncological outcomes of anti-PD1
to chemotherapy in the treatment of non-small-cell lung cancer.
Results: Overall survival (OR=0.68,95%CI=0.61-0.75, P<0.00001) and progression-free survival
(OR=0.84,95%CI=0.77-0.92, P=0.0002) were longer with anti-PD1 than with docetaxel in NSCLC.
Anti-PD1 was associated with even greater objective response rate than docetaxel
(OR=1.61,95%CI=1.16-2.24, P=0.004). Treatment-related adverse events of grade 3-5 did favor
anti-PD1 over docetaxel (OR=0.21,95%CI=0.10-0.42, P<0.00001).
Conclusions: Among patients with advanced NSCLC, we found that there was a superior survival
benefit and with a favorable safety profile with anti-PD1 than with docetaxel. More large-scale
randomized controlled trials are needed to identify relevant biomarkers that have an effect on
predicting the population that would most likely benefit from PD-1/PD-L1 for pretreated advanced